Pembrolizumab-chemotherapy for advanced oesophageal cancer

被引：0
|
作者：
Gil, Ziv [1 ,2 ]
Billan, Salem [3 ]
机构：
[1] Israel Inst Technol, Head & Neck Surg Unit, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
[2] Israel Inst Technol, Head & Neck Ctr, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
[3] Israel Inst Technol, Dept Oncol & Radiat, Head & Neck Ctr, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
来源：
LANCET | 2021年 / 398卷 / 10302期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：726 / 727
页数：2
相关论文
共 50 条
  • [31] Perioperative chemotherapy for oesophageal cancer
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 196 - 196
  • [32] Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer
    Petrasch, S
    Welt, A
    Reinacher, A
    Graeven, U
    König, M
    Schmiegel, W
    BRITISH JOURNAL OF CANCER, 1998, 78 (04) : 511 - 514
  • [33] Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial
    Powles, T.
    Gschwend, J. E.
    Loriot, Y.
    Bellmunt, J.
    Geczi, L.
    Vulsteke, C.
    Abdelsalam, M.
    Gafanov, R.
    Bae, W. K.
    Revesz, J.
    Yamamoto, Y.
    Anido, U.
    Su, W-P.
    Fleming, M.
    Markus, M.
    Feng, D.
    Poehlein, C.
    Alva, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer
    S Petrasch
    A Welt
    A Reinacher
    U Graeven
    M König
    W Schmiegel
    British Journal of Cancer, 1998, 78 : 511 - 514
  • [35] Neoadjuvant chemotherapy in "technically" inoperable locally advanced oesophageal (0) and gastro-oesophageal junction (GOJ) cancer
    Cheong, KA
    Chrystal, K
    Forshaw, M
    Gossage, J
    Galani, E
    Botha, A
    Mason, R
    Harper, PG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 347S - 347S
  • [36] Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
    Sun, Jong-Mu
    Shen, Lin
    Shah, Manish A.
    Enzinger, Peter
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chul
    Mansoor, Wasat
    Li, Shau-Hsuan
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Goekkurt, Eray
    Hara, Hiroki
    Antunes, Luis
    Fountzilas, Christos
    Tsuji, Akihito
    Oliden, Victor Castro
    Liu, Qi
    Shah, Sukrut
    Bhagia, Pooja
    Kato, Ken
    LANCET, 2021, 398 (10302): : 759 - 771
  • [37] The use of lenvatinib and pembrolizumab after platinum-based chemotherapy in advanced endometrial cancer
    Asmal, M.
    Ramiah, P.
    SA PHARMACEUTICAL JOURNAL, 2024, 91 (06) : 35 - 36
  • [38] Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
    Slater, Susanna
    Cunningham, David
    LANCET, 2023, 401 (10391): : 1826 - 1827
  • [39] Impact of peridiagnostic genetic counseling and germline testing on treatment decisions for patients with triple negative breast cancer undergoing pembrolizumab-chemotherapy neoadjuvant approach.
    Ines Bruno, Luisina
    Alberto, Guillermo
    Sabina Lapuchesky, Laura
    Rodriguez, Andres
    Waisberg, Federico
    Hernan Enrico, Diego
    Alexis Ostinelli, Cristian
    Alfredo Paletta, Claudio
    Enrique Petracci, Fernando
    Amat, Mora
    Teresa Pombo, Maria
    Rivero, Sergio
    Andres Colo, Federico
    Martin Loza, Carlos
    Yamila Fabiano, Veronica
    Chacon, Reinaldo D.
    Rodrigo Chacon, Matias
    Carlos Nadal, Jorge
    Nervo, Adrian
    Victoria Costanzo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Pembrolizumab plus Chemotherapy in Lung Cancer
    Sun, Ryan
    Rich, Michael W.
    Wei, Lee-Jen
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11):
12345